Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).

被引：0
|
作者：
de Bono, JS
Steele, N
Vidal, L
Reid, A
Marriott, C
Tjornelund, J
Shaw, H
Plumb, J
Molife, R
Morrison, R
Fong, P
Buhl-Jensen, P
Rasmussen, A
Evans, TRJ
机构：
[1] Royal Marsden NHS Trust, Sutton, Surrey, England
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] TopoTargets, Copenhagen, Denmark
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9121S / 9121S
页数：1
相关论文
共 50 条
  • [41] Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors
    Gore, L
    Holden, SN
    Basche, M
    Raj, SKS
    Arnold, I
    O'Bryant, C
    Witta, S
    Rohde, B
    McCoy, C
    Eckhardt, SG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [42] A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
    Kelly, W.
    Petrylak, D.
    Blumenschein, G.
    Lassen, U.
    Jensen, P. Buhl
    DeBono, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 127
  • [43] A phase II trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A trial of the PMH Phase II Consortium
    Mackay, Helen J.
    Hirte, Hal
    Covens, Al
    MacAlpine, Katrina
    Wang, Lisa
    Tsao, Ming
    Pan, James
    Zweibel, James
    Oza, Amit M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3388S - 3388S
  • [44] A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial
    Mackay, H.
    Hirte, H. W.
    Covens, A.
    MacAlpine, K.
    Wang, L.
    Tsao, M. S.
    Pan, J.
    Zwiebel, J. A.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [46] First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study
    Bitzer, M.
    Horger, M.
    Ebert, M. P.
    Ganten, T.
    Woerns, M. A.
    Hauns, B.
    Mais, A.
    Jankowsky, R.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
  • [48] Histone deacetylase inhibitor Belinostat (PXD-101) represses androgen receptor expression and acts synergistically with castration and bicalutamide treatment to inhibit prostate cancer growth hormone refractory models
    Festuccia, C.
    Gravina, G. L.
    Marampon, F.
    Biordi, L. A.
    Ricevuto, E.
    Ficorella, C.
    Tombolini, V.
    EJC SUPPLEMENTS, 2010, 8 (07): : 62 - 63
  • [49] ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)
    Raje, Noopur
    Vogl, Dan T.
    Hari, Parameswaran N.
    Jagannath, Sundar
    Jones, Simon S.
    Supko, Jeffrey G.
    Leone, Gina
    Wheeler, Catherine
    Orlowski, Robert Z.
    Richardson, Paul G.
    Lonial, Sagar
    BLOOD, 2013, 122 (21)
  • [50] First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies
    Ang, J. E.
    Hauns, B.
    Mais, A.
    Parker, A.
    Lal, R.
    Olmos, D.
    Mollenhauer, M.
    Walz, A.
    de Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 123 - 124
12345